<DOC>
	<DOC>NCT01242228</DOC>
	<brief_summary>This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and DPP-4 inhibitor in Japanese patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients</brief_title>
	<detailed_description>This is a 52-week multi-center, open-label, non-comparative study in subjects with type 2 diabetes mellitus who have inadequate glycemic control on a DPP-4 inhibitor alone. Dosage may be increased during the treatment period if subjects fulfill increasing criteria and the investigators adjudicate that no impact for subjects safety.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Type 2 diabetic patients receiving with DPP4 inhibitor monotherapy for at least 4 weeks HbA1c value between 6.5 and 9.5% Body Mass Index (BMI) 20.0 45.0 kg/m2 Type 1 diabetes mellitus patients Serum creatinine &gt; upper limit of normal Proteinuria (albumin/creatinine ratio &gt; 300mg/g) Dysuria and/or urinary tract infection, genital infection Significant renal, hepatic or cardiovascular diseases Severe gastrointestinal diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Dipeptidyl peptidase-4 inhibitor</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>long-term safety</keyword>
</DOC>